HERCULES CAPITAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.96 USD | +0.58% |
|
+5.39% | +13.74% |
| Apr. 03 | KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. for $100 million. | CI |
| Mar. 26 | Bluebird bio to Restate Financial Statements; Shares Fall | MT |
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 9.22 for the current year.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Investment Management & Fund Operators
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +13.74% | 3.02B | B- | ||
| +31.41% | 12.02B | - | - | |
| +3.40% | 1.41B | D+ | ||
| -8.46% | 1.22B | - | - | |
| +1.15% | 612M | - | ||
| +37.56% | 584M | - | D+ | |
| -15.89% | 561M | - | B+ | |
| +39.13% | 505M | - | - | |
| -4.17% | 491M | - | - | |
| +3.90% | 304M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- HTGC Stock
- Ratings Hercules Capital, Inc.
